• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.

作者信息

Tabata T, Shoji S, Morita A, Emoto M, Inoue T, Miki T, Nishizawa Y, Morii H

机构信息

Division of Medicine, Inoue Hospital, Suita, Japan.

出版信息

J Nutr Sci Vitaminol (Tokyo). 1991 Dec;37 Suppl:S105-12. doi: 10.3177/jnsv.37.supplement_s105.

DOI:10.3177/jnsv.37.supplement_s105
PMID:1820436
Abstract

Phosphorus (P) retention plays an important role in the pathogenesis of secondary hyperparathyroidism (2nd HPT) in chronic renal failure. In recent years, periodic intravenous or intermittent oral administration of high doses of 1,25(OH)2D3 has been reported to improve severe 2nd HPT in hemodialysis patients. The present study was performed to determine the effects of dietary P restriction on 2nd HPT in hemodialysis patients treated with intermittent oral high-dose 1,25(OH)2D3. A high dose of 1,25(OH)2D3 was administered orally twice a week at the end of hemodialysis in 20 hemodialysis patients with 2nd HPT. Dietary P content was estimated from records of the patients' food intake, made twice during the treatment period. Based on this information, dietitians developed appropriate meal plans and instructed the patients. After 8 weeks of the treatment, serum c-parathyroid hormone (c-PTH) and alkaline phosphatase (ALP) levels decreased significantly, from 18.8 +/- 1.9 ng/ml and 347.1 +/- 30.7 U/liter to 9.4 +/- 1.2 ng/ml and 268.3 +/- 19.6 U/liter, respectively. Serum P levels increased gradually during the first 4 weeks of the treatment. Dietary P intake was reduced significantly, from 908 +/- 49 mg/day to 734 +/- 39 mg/day, after the nutritional instructions. As a result of the dietary P restrictions, serum P levels were significantly decreased in the 8th week as compared with those in the 4th week. Serum Ca levels remained unchanged throughout the observation period. There was a significant relationship between the mean values for serum P levels during the study and the percent suppression of serum c-PTH.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

相似文献

1
Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.
J Nutr Sci Vitaminol (Tokyo). 1991 Dec;37 Suppl:S105-12. doi: 10.3177/jnsv.37.supplement_s105.
2
1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.1α(OH)D3 一α-羟基胆钙化醇——一种活性维生素 D 类似物。关于慢性透析的尿毒症患者继发性甲状旁腺功能亢进症预防和治疗的临床研究。
Dan Med Bull. 2008 Nov;55(4):186-210.
3
Suppression of secondary hyperparathyroidism in chronic dialysis patients by single oral weekly dose of 1,25-dihydroxycholecalciferol.
Intern Med. 1993 Sep;32(9):695-701. doi: 10.2169/internalmedicine.32.695.
4
The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
Nephron. 1991;57(1):23-8. doi: 10.1159/000186210.
5
Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.静脉注射1,25 - 二羟胆钙化醇对尿毒症患者继发性甲状旁腺功能亢进有显著抑制作用。
J Clin Invest. 1984 Dec;74(6):2136-43. doi: 10.1172/JCI111639.
6
Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.间歇性口服1,25(OH)₂D₃疗法对透析患者骨钙素的影响。
Endocrinol Jpn. 1991 Oct;38(5):479-83. doi: 10.1507/endocrj1954.38.479.
7
Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients.
Miner Electrolyte Metab. 1994;20(3):97-102.
8
Treatment of severe secondary hyperparathyroidism with administration of calcium carbonate, intermittent high oral doses of 1,25-dihydroxyvitamin D3 and dialysate with 3 mEq/1 calcium concentration.
Am J Nephrol. 1993;13(2):149-54. doi: 10.1159/000168606.
9
'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study.慢性血液透析患者中“口服脉冲式”与静脉注射骨化三醇疗法的前瞻性随机研究
Nephron. 1997;77(3):267-72. doi: 10.1159/000190286.
10
Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis.静脉注射骨化三醇治疗血液透析儿童的甲状旁腺功能亢进症。
Pediatr Nephrol. 2005 May;20(5):622-30. doi: 10.1007/s00467-004-1792-6. Epub 2005 Mar 23.